regulatory status raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-15. Anything still debated is marked as such rather than presented as settled.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
While it was decorated for valor in the conflict, it also triggered the only episode of open rebellion on the Italian front, in June 1917. The cause was the order to return to the trenches despite the fact that the soldiers had just been sent to the rear to rest. Many soldiers from the 142nd Regiment revolted against the officers, killing three of them along with four carabinieri. After quelling the rebellion with the help of cavalry, mobile artillery and carabinieri, the General Staff decided to punish the Brigade, as a warning against other uprisings: 28 soldiers were shot, while the survivors were sent back to the front under armed escort. The Duke investigated the causes of the rebellion while serving on the Karst Plateau. He blamed the unequal treatment versus other brigades, which enjoyed easier rest shifts. The report of General Tettoni, commander of VII Army Corps, instead blamed it on socialist propaganda and newspaper reports of the Czar's defeat in Russia. The mostly peasant soldiers had been promised an allocation of land derived from large estates after the war. The lack of political will in the implementation of this promise, together with nationalistic tensions due to the Fiume and Dalmatian question, generated a climate of resentment and social unrest, which turned into strikes, anti-government demonstrations and occupations of uncultivated land by the peasants, who organized in leagues or federations of different political colorings.
(2026) describe a late Pliocene proboscidean and even-toed ungulate assemblage (the Dongyancun Fauna) from the Sanmenxia Basin (Zhongtiao Mountains; China), including the first reported Pliocene record of Leptobos in northern China, and providing evidence of composition of large herbivore assemblages in northern China shortly before Quaternary climate changes, arrival of true horses and appearance of Mammuthus meridionalis. Shidqi et al. (2026) review the fossil record of Pleistocene mammals from Sumatra (Indonesia), reporting evidence of presence of mammals with Indochinese and Sundaic affinities and evidence of limited taxonomic losses since the late Middle Pleistocene. Zhang et al. (2026) report the discovery of new fossil material of Early Pleistocene mammals from the Yeka locality in the Shangri-La region (Yunnan, China), and interpret the composition of the studied assemblage as indicative of an environment including a forest mixed with a grassland landscape. Linchamps et al. (2026) study the composition of the Early Pleistocene small mammal assemblage from the Gondolin GD2 locality (South Africa), interpreted as indicative of environments dominated by grassland and open savannas.
=== Extraction === Oil extraction is simply the removal of oil from the reservoir (oil pool). There are many methods of extracting the oil from the reservoirs for example; mechanical shaking, water-in-oil emulsion, and specialty chemicals called demulsifiers that separate the oil from water. Oil extraction is costly and often environmentally damaging. Offshore exploration and extraction of oil disturb the surrounding marine environment.
== Genetic coding == In 1993, the gene sequence of CK1δ was initially described by Graves et al. who isolated the cDNA from testicles of rats. After sequencing and characterization of the gene, the construct was described as a 1284 nucleotide sequence resulting in a protein consisting of 428 amino acids after transcription. The molecular weight of the according protein was published as 49 kDa. Three years later, the same gene was identified in humans. The human CSNK1D contains 1245 nucleotides and is transcribed into a protein consisting of 415 amino acids. Ever since, CK1δ was investigated and described in various animals, plants, as well as parasites (Caenorhabditis elegans, 1998; Drosophila melanogaster, 1998; Mus musculus, 2002; Xenopus laevis, 2002.)
Sources: en.wikipedia.org
=== Fourth Republic === June 27, 1947: Decree creating the medical code of ethics; it includes provisions on therapeutic abortion. November 1947: Germaine Poinso-Chapuis becomes France's first female minister, for Public Health and Population; the second female minister in the country will be Simone Veil in 1974. November 5, 1947: Decree implementing the April 24, 1946, law establishing a sanitary and social registry of prostitution. September 1, 1948: Law modifying and codifying legislation on relations between landlords and tenants or occupants of residential or professional premises and establishing housing allowances. August 11, 1950: Law publishing ILO Convention No. 3 (adopted on November 29, 1919) and authorizing its ratification; this convention concerns the employment of pregnant and newly delivered women. October 15, 1951: Decree on the status of female military personnel. December 10, 1952: Law authorizing the ratification of ILO Convention No. 100, concerning "equal remuneration for men and women for work of equal value." May 17, 1954: Decree on the family record book: contents and definitions of the records and extracts to be included. August 6, 1955: Law setting the supplementary budget for agricultural family benefits for fiscal years 1955 and 1956; notably establishes a "housewife allowance," granted to the "head of household" under certain conditions. November 28, 1955: Decree on the medical code of ethics, modifying the previous one.
== Bibliography == K.F. Warner, "Boning Lamb Cuts", Leaflet 74, U.S. Department of Agriculture, Bureau of Animal Industry, June 1931. full text. Bob Kennard, "Much ado about mutton". Ludlow: Merlin Unwin, 2014.
=== Efficacy of medication and psychotherapy === Antidepressants are statistically superior to placebo but their overall effect is low-to-moderate. In that respect they often did not exceed the National Institute for Health and Clinical Excellence criteria for a "clinically significant" effect. In particular, the effect size was very small for moderate depression but increased with severity, reaching "clinical significance" for very severe depression. These results were consistent with the earlier clinical studies in which only patients with severe depression benefited from either psychotherapy or treatment with an antidepressant, imipramine, more than from the placebo treatment. Despite obtaining similar results, the authors argued about their interpretation. One author concluded that there "seems little evidence to support the prescription of antidepressant medication to any but the most severely depressed patients, unless alternative treatments have failed to provide benefit." The other author agreed that "antidepressant 'glass' is far from full" but disagreed "that it is completely empty". He pointed out that the first-line alternative to medication is psychotherapy, which does not have superior efficacy. Antidepressants in general are as effective as psychotherapy for major depression, and this conclusion holds true for both severe and mild forms of MDD. In contrast, medication gives better results for dysthymia. The subgroup of SSRIs may be slightly more efficacious than psychotherapy.
This deposit is blue naturally and turns green when heated due to dehydration. It is restricted to a mine-riddled region in Nishapur, the 2,012 m (6,601 ft) mountain peak of Ali-mersai near Mashhad, the capital of Khorasan Province, Iran. Weathered and broken trachyte is host to the turquoise, which is found both in situ between layers of limonite and sandstone and amongst the scree at the mountain's base. These workings are the oldest known, together with those of the Sinai Peninsula. Iran also has turquoise mines in Semnan and Kerman provinces.
Magnetic resonance spectroscopy (MRS) is used to measure the levels of different metabolites in body tissues, which can be achieved through a variety of single voxel or imaging-based techniques. The MR signal produces a spectrum of resonances that corresponds to different molecular arrangements of the isotope being "excited". This signature is used to diagnose certain metabolic disorders, especially those affecting the brain, and to provide information on tumor metabolism. Magnetic resonance spectroscopic imaging (MRSI) combines both spectroscopic and imaging methods to produce spatially localized spectra from within the sample or patient. The spatial resolution is much lower (limited by the available SNR), but the spectra in each voxel contains information about many metabolites. Because the available signal is used to encode spatial and spectral information, MRSI requires high SNR achievable only at higher field strengths (3 T and above). The high procurement and maintenance costs of MRI with extremely high field strengths inhibit their popularity. However, recent compressed sensing-based software algorithms (e.g., SAMV) have been proposed to achieve super-resolution without requiring such high field strengths.
Sources: en.wikipedia.org
The Constitution of the short-lived Zimbabwe Rhodesia, which saw a black-led government elected for the first time, reserved 28 of the 100 parliamentary seats for whites. The independence constitution agreed at Lancaster House watered those provisions down and reserved 20 out of 100 seats for whites in the House of Assembly and 8 out of 40 seats in the Senate. The constitution prohibited Zimbabwe authorities from altering the Constitution for seven years without unanimous consent and required a three-quarters vote in Parliament for a further three years. The government amended the Constitution in 1987 to abolish the seats reserved for whites, and replace the office of prime minister with an executive president. In 1990, the government abolished the Senate.
==== MeSH D12.776.467.100.800 – vascular endothelial growth factors ==== MeSH D12.776.467.100.800.200 – vascular endothelial growth factor a MeSH D12.776.467.100.800.300 – vascular endothelial growth factor b MeSH D12.776.467.100.800.400 – vascular endothelial growth factor c MeSH D12.776.467.100.800.500 – vascular endothelial growth factor d MeSH D12.776.467.100.800.600 – vascular endothelial growth factor, endocrine-gland-derived
As with all opioids, the effects of fentanyl can be reversed with naloxone, or other opiate antagonists. Naloxone is increasingly available to the public. Illicitly synthesized fentanyl powder has also appeared on the United States market. Because of the extremely high strength of pure fentanyl powder, it is very difficult to dilute appropriately; often the resulting mixture may be far too strong and, therefore, very dangerous. Some heroin dealers mix fentanyl powder with heroin to increase potency or compensate for low-quality heroin. In 2006, illegally manufactured, non-pharmaceutical fentanyl, often mixed with cocaine or heroin, caused an outbreak of overdose deaths in the United States and Canada. Deaths were heavily concentrated in the cities of Dayton, Ohio; Chicago, Illinois; Detroit, Michigan; and Philadelphia, Pennsylvania.
== Further reading == Zachara, Natasha; Akimoto, Yoshihiro; Hart, Gerald W. (2015), Varki, Ajit; Cummings, Richard D.; Esko, Jeffrey D.; Stanley, Pamela (eds.), "The O-GlcNAc Modification", Essentials of Glycobiology (3rd ed.), Cold Spring Harbor Laboratory Press, PMID 28876858.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.